Lv3
318 积分 2022-10-07 加入
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
3个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
4个月前
已完结
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
6个月前
已完结
Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity
6个月前
已完结
EGFR Mutations and Lung Cancer
6个月前
已完结
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
6个月前
已完结
[Postoperative Recurrence of ROS1‒Positive Pulmonary Adenocarcinoma after 19 Years]
6个月前
已关闭
Evolving roles of MET as a therapeutic target in NSCLC and beyond
6个月前
已完结
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
7个月前
已完结
皖公网安备34019202002308
